07:00 , Mar 14, 2016 |  BC Week In Review  |  Company News

Boehringer Ingelheim, AbbVie deal

AbbVie and Boehringer partnered to develop and commercialize Boehringer’s BI 655066 and BI 655064. Boehringer will receive $595 million up front and is eligible for undisclosed milestones plus royalties. Both partners will...
07:00 , Mar 14, 2016 |  BioCentury  |  Product Development

The missing piece

In preparation for biosimilar competition for Humira adalimumab, AbbVie Inc. is developing a portfolio of products intended to treat the blockbuster's many indications. Last week's deal with Boehringer Ingelheim GmbH added a large missing piece,...
01:22 , Mar 8, 2016 |  BC Extra  |  Company News

AbbVie, BI enter immunology deal

AbbVie Inc. (NYSE:ABBV) and Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered to develop and commercialize a pair of Boehringer's immunology candidates, including BI 655066, a mAb against IL-23 that is in Phase III for moderate to...